AUTHOR=Zelba Henning , Rabsteyn Armin , Bartsch Oliver , Kyzirakos Christina , Kayser Simone , Seibold Marcel , Harter Johannes , Latzer Pauline , Hadaschik Dirk , Battke Florian , Golf Alexander , Rettig Matthew B. , Biskup Saskia 

TITLE=Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer

JOURNAL=Frontiers in Immunology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1271449

DOI=10.3389/fimmu.2023.1271449

ISSN=1664-3224

ABSTRACT=While the first vaccine induced only one robust CD4+ T-cell response after 21 vaccinations, co-vaccination of HLA class I and II peptides induced multiple strong and durable CD4+ and CD8+ T-cell responses already after sixth vaccinations. The vaccine-induced immune responses were robust and polyfunctional. PSA remained undetectable for 51 months.The results presented here implicate that neoantigen-targeting vaccines might be considered for those cancer subtypes where therapeutic options are limited. Furthermore, our findings suggest that both HLA class I and II restricted peptides should be considered for future peptide vaccination trials.